Development and validation of a risk score for serious infection in patients with rheumatoid arthritis
Identifieur interne : 001407 ( Main/Exploration ); précédent : 001406; suivant : 001408Development and validation of a risk score for serious infection in patients with rheumatoid arthritis
Auteurs : Cynthia S. Crowson [États-Unis] ; Deana D. Hoganson [États-Unis] ; Patrick D. Fitz-Gibbon [États-Unis] ; Eric L. Matteson [États-Unis]Source :
- Arthritis & Rheumatism [ 0004-3591 ] ; 2012-09.
English descriptors
- Teeft :
- Arthritis, Arthritis rheum, Biologic, Biologic agents, Biologic therapy, Biologic treatment, British society, Cardiovascular comorbidities, Chronic lung disease, Cohort, Comorbidities, Comorbidity, Coronary heart disease, Corticosteroid, Crowson, Decile, Diabetes mellitus, Disease activity, Disease characteristics, Erythrocyte sedimentation rate, Extraarticular, Extraarticular manifestations, First infection, Followup, Heart failure, Infection, Infection risk, Intravenous antibiotics, Leukopenia, Lymphopenia, Matteson, Mayo clinic, Mellitus, Multivariable, Multivariable model, Neutropenia, Next year, Nonlinear effects, Olmsted county, Original cohort, Past year, Potential predictors, Predictor, Previous infection, Previous infections, Referent, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatoid factor, Rheumatoid lung disease, Rheumatoid vasculitis, Rheumatology, Rheumatology biologics, Risk factors, Risk score, Rochester epidemiology project, Serious infection, Serious infections, Statistic, Statistical significance, Validation, Validation cohort.
Abstract
Objective: Infection risk is increased in patients with rheumatoid arthritis (RA), and accurate assessment of the risk of infection could inform clinical decision‐making. This study was undertaken to develop and validate a score to predict the 1‐year risk of serious infection in patients with RA. Methods: We studied a population‐based cohort of Olmsted County, Minnesota residents with incident RA ascertained in 1955–1994 whose members were followed up longitudinally, via complete medical records, until January 2000. The validation cohort included residents with incident RA ascertained in 1995–2007. The outcome measure included all serious infections (requiring hospitalization or intravenous antibiotics). Potential predictors were examined using multivariable Cox models. The risk score was estimated directly from the multivariable model, and performance was assessed in the validation cohort using Harrell's C statistic. Results: Among the 584 RA patients in the original cohort (72% female; mean age 57.5 years), who were followed up for a median of 9.9 years, 252 had ≥1 serious infection (646 total infections). Components of the risk score included age, previous serious infection, corticosteroid use, elevated erythrocyte sedimentation rate, extraarticular manifestations of RA, and comorbidities (coronary heart disease, heart failure, peripheral vascular disease, chronic lung disease, diabetes mellitus, alcoholism). Validation analysis revealed good discrimination (C statistic 0.80). Conclusion: RA disease characteristics and comorbidities can be used to accurately assess the risk of serious infection in patients with RA. Knowledge of risk of serious infection in RA patients can influence clinical decision making and inform strategies to reduce and prevent the occurrence of these infections.
Url:
DOI: 10.1002/art.34530
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002715
- to stream Istex, to step Curation: 002715
- to stream Istex, to step Checkpoint: 000416
- to stream Main, to step Merge: 001408
- to stream Main, to step Curation: 001407
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development and validation of a risk score for serious infection in patients with rheumatoid arthritis</title><author><name sortKey="Crowson, Cynthia S" sort="Crowson, Cynthia S" uniqKey="Crowson C" first="Cynthia S." last="Crowson">Cynthia S. Crowson</name></author><author><name sortKey="Hoganson, Deana D" sort="Hoganson, Deana D" uniqKey="Hoganson D" first="Deana D." last="Hoganson">Deana D. Hoganson</name></author><author><name sortKey="Fitz Ibbon, Patrick D" sort="Fitz Ibbon, Patrick D" uniqKey="Fitz Ibbon P" first="Patrick D." last="Fitz-Gibbon">Patrick D. Fitz-Gibbon</name></author><author><name sortKey="Matteson, Eric L" sort="Matteson, Eric L" uniqKey="Matteson E" first="Eric L." last="Matteson">Eric L. Matteson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:903C6C44346E1B88F99ADDE5112894440FEF4997</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/art.34530</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-4M6F56D9-7/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002715</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002715</idno><idno type="wicri:Area/Istex/Curation">002715</idno><idno type="wicri:Area/Istex/Checkpoint">000416</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000416</idno><idno type="wicri:doubleKey">0004-3591:2012:Crowson C:development:and:validation</idno><idno type="wicri:Area/Main/Merge">001408</idno><idno type="wicri:Area/Main/Curation">001407</idno><idno type="wicri:Area/Main/Exploration">001407</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Development and validation of a risk score for serious infection in patients with rheumatoid arthritis</title><author><name sortKey="Crowson, Cynthia S" sort="Crowson, Cynthia S" uniqKey="Crowson C" first="Cynthia S." last="Crowson">Cynthia S. Crowson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Mayo Clinic, Rochester</wicri:cityArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Correspondence address: Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Hoganson, Deana D" sort="Hoganson, Deana D" uniqKey="Hoganson D" first="Deana D." last="Hoganson">Deana D. Hoganson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Mayo Clinic, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Fitz Ibbon, Patrick D" sort="Fitz Ibbon, Patrick D" uniqKey="Fitz Ibbon P" first="Patrick D." last="Fitz-Gibbon">Patrick D. Fitz-Gibbon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Mayo Clinic, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Matteson, Eric L" sort="Matteson, Eric L" uniqKey="Matteson E" first="Eric L." last="Matteson">Eric L. Matteson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Mayo Clinic, Rochester</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Arthritis & Rheumatism</title><title level="j" type="alt">ARTHRITIS AND RHEUMATISM</title><idno type="ISSN">0004-3591</idno><idno type="eISSN">1529-0131</idno><imprint><biblScope unit="vol">64</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="2847">2847</biblScope><biblScope unit="page" to="2855">2855</biblScope><biblScope unit="page-count">9</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-09">2012-09</date></imprint><idno type="ISSN">0004-3591</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0004-3591</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Arthritis</term><term>Arthritis rheum</term><term>Biologic</term><term>Biologic agents</term><term>Biologic therapy</term><term>Biologic treatment</term><term>British society</term><term>Cardiovascular comorbidities</term><term>Chronic lung disease</term><term>Cohort</term><term>Comorbidities</term><term>Comorbidity</term><term>Coronary heart disease</term><term>Corticosteroid</term><term>Crowson</term><term>Decile</term><term>Diabetes mellitus</term><term>Disease activity</term><term>Disease characteristics</term><term>Erythrocyte sedimentation rate</term><term>Extraarticular</term><term>Extraarticular manifestations</term><term>First infection</term><term>Followup</term><term>Heart failure</term><term>Infection</term><term>Infection risk</term><term>Intravenous antibiotics</term><term>Leukopenia</term><term>Lymphopenia</term><term>Matteson</term><term>Mayo clinic</term><term>Mellitus</term><term>Multivariable</term><term>Multivariable model</term><term>Neutropenia</term><term>Next year</term><term>Nonlinear effects</term><term>Olmsted county</term><term>Original cohort</term><term>Past year</term><term>Potential predictors</term><term>Predictor</term><term>Previous infection</term><term>Previous infections</term><term>Referent</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Rheumatoid factor</term><term>Rheumatoid lung disease</term><term>Rheumatoid vasculitis</term><term>Rheumatology</term><term>Rheumatology biologics</term><term>Risk factors</term><term>Risk score</term><term>Rochester epidemiology project</term><term>Serious infection</term><term>Serious infections</term><term>Statistic</term><term>Statistical significance</term><term>Validation</term><term>Validation cohort</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: Infection risk is increased in patients with rheumatoid arthritis (RA), and accurate assessment of the risk of infection could inform clinical decision‐making. This study was undertaken to develop and validate a score to predict the 1‐year risk of serious infection in patients with RA. Methods: We studied a population‐based cohort of Olmsted County, Minnesota residents with incident RA ascertained in 1955–1994 whose members were followed up longitudinally, via complete medical records, until January 2000. The validation cohort included residents with incident RA ascertained in 1995–2007. The outcome measure included all serious infections (requiring hospitalization or intravenous antibiotics). Potential predictors were examined using multivariable Cox models. The risk score was estimated directly from the multivariable model, and performance was assessed in the validation cohort using Harrell's C statistic. Results: Among the 584 RA patients in the original cohort (72% female; mean age 57.5 years), who were followed up for a median of 9.9 years, 252 had ≥1 serious infection (646 total infections). Components of the risk score included age, previous serious infection, corticosteroid use, elevated erythrocyte sedimentation rate, extraarticular manifestations of RA, and comorbidities (coronary heart disease, heart failure, peripheral vascular disease, chronic lung disease, diabetes mellitus, alcoholism). Validation analysis revealed good discrimination (C statistic 0.80). Conclusion: RA disease characteristics and comorbidities can be used to accurately assess the risk of serious infection in patients with RA. Knowledge of risk of serious infection in RA patients can influence clinical decision making and inform strategies to reduce and prevent the occurrence of these infections.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Minnesota</li></region></list><tree><country name="États-Unis"><region name="Minnesota"><name sortKey="Crowson, Cynthia S" sort="Crowson, Cynthia S" uniqKey="Crowson C" first="Cynthia S." last="Crowson">Cynthia S. Crowson</name></region><name sortKey="Crowson, Cynthia S" sort="Crowson, Cynthia S" uniqKey="Crowson C" first="Cynthia S." last="Crowson">Cynthia S. Crowson</name><name sortKey="Crowson, Cynthia S" sort="Crowson, Cynthia S" uniqKey="Crowson C" first="Cynthia S." last="Crowson">Cynthia S. Crowson</name><name sortKey="Fitz Ibbon, Patrick D" sort="Fitz Ibbon, Patrick D" uniqKey="Fitz Ibbon P" first="Patrick D." last="Fitz-Gibbon">Patrick D. Fitz-Gibbon</name><name sortKey="Hoganson, Deana D" sort="Hoganson, Deana D" uniqKey="Hoganson D" first="Deana D." last="Hoganson">Deana D. Hoganson</name><name sortKey="Matteson, Eric L" sort="Matteson, Eric L" uniqKey="Matteson E" first="Eric L." last="Matteson">Eric L. Matteson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001407 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001407 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:903C6C44346E1B88F99ADDE5112894440FEF4997
|texte= Development and validation of a risk score for serious infection in patients with rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |